Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Total Liabilities (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Total Liabilities for 5 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For Q4 2025, Total Liabilities fell 76.32% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, down 76.32%, while the annual FY2025 figure was $6.6 million, 76.32% down from the prior year.
  • Total Liabilities hit $6.6 million in Q4 2025 for Kezar Life Sciences, down from $14.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $33.7 million in Q4 2023 and bottomed at $6.6 million in Q4 2025.
  • Average Total Liabilities over 5 years is $22.6 million, with a median of $21.9 million recorded in 2022.
  • Year-over-year, Total Liabilities surged 105.78% in 2022 and then tumbled 76.32% in 2025.
  • Kezar Life Sciences' Total Liabilities stood at $21.1 million in 2021, then soared by 41.03% to $29.7 million in 2022, then rose by 13.37% to $33.7 million in 2023, then decreased by 17.52% to $27.8 million in 2024, then crashed by 76.32% to $6.6 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $6.6 million, $14.8 million, and $17.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.